Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 31;8(3):108.
doi: 10.3390/antibiotics8030108.

Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?

Stuart K Pitman  1   2 , Uyen T P Hoang  3 , Caren H Wi  3 , Mona Alsheikh  3 , Dakota A Hiner  3 , Kelly M Percival  4
Affiliations
Review

Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?

Stuart K Pitman et al. Antibiotics (Basel). .

Abstract

Fluoroquinolones are a widely-prescribed, broad-spectrum class of antibiotics with several oral formulations notable for their high bioavailability. For certain infections, fluoroquinolones are the first line or only treatment choice. When administered orally, fluoroquinolones require proper administration to ensure adequate systemic absorption and, thereby, protect patients from treatment failure. Oral drug preparations that contain multivalent cations are well known to chelate with fluoroquinolones in the gastrointestinal tract; co-administration may lead to clinically significant decreases in oral fluoroquinolone bioavailability and an overall increase in fluoroquinolone-resistant bacteria. Based on a search and evaluation of the literature, this focused review describes oral fluoroquinolone-multivalent cation drug-drug interactions and their magnitude and offers several clinical management strategies for these potentially clinically significant interactions.

Keywords: antibiotic; cation; drug interaction; fluoroquinolone; oral; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Preheim L.C., Cuevas TA., Roccaforte J.S., Mellencamp M.A., Bittner M.J. Ciprofloxacin and antacids. Lancet. 1986;2:48. doi: 10.1016/S0140-6736(86)92596-1. - DOI - PubMed
    1. Rosenau E.J., Merth K.D. Ciprofloxacin: Case of multiple interactions. Can. J. Hosp. Pharm. 1993;46:88–90.
    1. Noyes M., Polk R.E. Norfloxacin and absorption of magnesium-aluminum. Ann. Intern. Med. 1988;109:168–169. doi: 10.7326/0003-4819-109-2-168_2. - DOI - PubMed
    1. Spivey J.M., Cummings D.M., Pierson N.R. Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy. 1996;16:314–316. - PubMed
    1. Mallet L., Huang A. Coadministration of gatifloxacin and multivitamin preparation containing minerals: Potential treatment failure in an elderly patient. Ann. Pharmacother. 2005;39:150–152. doi: 10.1345/aph.1E392. - DOI - PubMed

LinkOut - more resources